



Line probe assays for detection of drug-resistant tuberculosis

Interpretation and reporting manual
for laboratory staff and clinicians



Line probe assays for detection of drug-resistant tuberculosis

Interpretation and reporting manual for laboratory staff and clinicians



Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for laboratory staff and clinicians

ISBN 978-92-4-004666-5 (electronic version)

ISBN 978-92-4-004667-2 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for laboratory staff and clinicians. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Cover image by © Alicephotography. Design by minimum graphics.

Contents

Acknowledgements	v
Acronyms and abbreviations	vi
Glossary	vii
Preface	viii
Introduction	1
Principle of the line probe assay	2
GenoType MTBDR <i>plus</i> version 2	3
GenoType MTBDRs/ version 2	4
Interpretation and reporting	4
Revisions to manufacturers' interpretations	5
Definition of additional follow-up of diagnosis to guide initiation of appropriate treatment	8
Interpretation of first-line line probe assay results	10
Rifampicin	10
Isoniazid	12
Interpretation of second-line line probe assay results	14
Fluoroquinolones	14
Amikacin	17
Assessment of drug-resistant cases based on second-line line probe assay results	19
Case 1. No resistance mutations detected or inferred in any of the genomic regions included in second-line line probe assay	19
Case 2. Detection of resistance mutations associated with high-level resistance to moxifloxacin	20
Case 3. Detection of mutations associated with at least low-level resistance to moxifloxacin	21
Case 4. Precise mutation unknown, only inferred for fluoroquinolones (i.e., <i>gyrA</i> and <i>gyrB</i>)	22
Case 5. Detection of mutations that cause resistance to amikacin	23
Case 6. Precise mutation unknown, only inferred, in the <i>rrs</i> region	24
Case 7. Precise mutation unknown, only inferred, in the <i>eis</i> region	25

References	26
Annex 1. Reporting format for first-line line probe assay results and practical examples	28
Annex 2. Reporting format for second-line line probe assay results and practical examples	29
Annex 3. Specific nucleotide changes detected with mutation probes	31

Acknowledgements

This manual is an updated version of the interpretation and reporting guide on line probe assays originally developed as a product of the Global Laboratory Initiative core group, by Elisa Tagliani (San Raffaele Scientific Institute, Milan, Italy), with contributions from Daniela Cirillo (San Raffaele Scientific Institute), Elisa Ardizzoni, Bouke de Jong and Leen Rigouts (Institute of Tropical Medicine, Antwerp, Belgium).

Coordination and substantial technical input were provided by Dennis Falzon, Christopher Gilpin, Lice González-Angulo, Alexei Korobitsyn, Fuad Mirzayev and Karin Weyer of the World Health Organization (WHO) Global TB Programme during finalization of the document. We thank past and current members of the Global Laboratory Initiative core group for their extensive contribution: Olajumoke Tubi Abiola, Maka Akhalaia, Heidi Albert, Heather Alexander, Uladzimir Antonenka, Martina Casenghi, Fernanda Dockhorn, Kathleen England, Lucilaine Ferrazoli, Christopher Gilpin, Petra de Haas, Patricia Hall, Sarder Tanzir Hossain, Marguerite Massinga Loembe, Alaine Umubyeyi Nyaruhirira, Daniel Orozco, Kaiser Shen, Thomas Shinnick, Alena Skrahina, Sabira Tahseen and Hung Van Nguyen.

WHO appreciates the feedback provided by the following partners and stakeholders: Ignacio Monedero-Recuero of the Global Drug-resistant TB Initiative, Paolo Miotto (San Raffaele Scientific Institute), Claudio Köser (Cambridge University, United Kingdom), Natalia Shubladze (Global Laboratory Initiative core group) and Soudeh Ehsani at the WHO Regional Office for Europe.

The Global Laboratory Initiative is a working group of the Stop TB Partnership. Development and publication of this document were made possible with financial support from the United States Agency for International Development.

Acronyms and abbreviations

7H10	Middlebrook 7H10 medium
Am	amikacin
CB	clinical breakpoint
CC	critical concentration
DST	drug-susceptibility testing
Eto	ethionamide
FQ	fluoroquinolone
H	isoniazid
Lfx	levofloxacin
LPA	line probe assay
MDR-TB	multidrug-resistant tuberculosis
MGIT	BACTEC™ Mycobacterial Growth Indicator Tube™ 960
Mfx	moxifloxacin
MIC	minimum inhibitory concentration
MTBC	<i>Mycobacterium tuberculosis</i> complex
MUT probe	mutation probe
Pto	prothionamide
PZA	pyrazinamide
QRDR	quinolone-resistance determining region
R	resistant
Rif	rifampicin
S	susceptible
SL-LPA	second-line line probe assay
TB	tuberculosis
WT	wild type

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31125

